Primary immunodeficiency is the indication that nearly every intravenous immunoglobulin product carries, and the only one with a dedicated permanent Medicare benefit for infusion at home. It is also where the vocabulary matters most: for common variable immunodeficiency (CVID) and the other antibody deficiencies, immunoglobulin is replacement therapy rather than immune suppression, and the labeled dose reflects that.
This article covers labeled replacement dosing, which products carry the indication, why products are not interchangeable, what IgG trough monitoring is for, and how the Medicare home IVIG benefit works. Prime Infusions operates 13 infusion centers across New York plus one in Atlanta and provides IVIG at Prime Infusions in center and at home.
What are primary immunodeficiency and CVID, and why is IVIG called replacement therapy?
Primary immunodeficiency, also called primary immune deficiency disease (PIDD), is a group of inherited disorders in which part of the immune system does not develop or function normally. In the antibody-deficiency subgroup, the body cannot produce enough functional immunoglobulin G (IgG), so ordinary bacteria cause repeated sinus, ear and lower respiratory infections. Common variable immunodeficiency (CVID) is the antibody deficiency most often diagnosed in adults; X-linked agammaglobulinemia and severe combined immunodeficiency (SCID) are others. Aetna Clinical Policy Bulletin 0206 on parenteral immunoglobulins, last reviewed June 18, 2026, groups SCID, CVID, DiGeorge syndrome and Wiskott-Aldrich syndrome together as primary immunodeficiencies for coverage purposes.
Intravenous immunoglobulin (IVIG) is concentrated human IgG purified from pooled donor plasma; the Asceniv package insert states the product is prepared from pooled plasma from not less than 1,000 donors. In primary immunodeficiency that IgG substitutes for antibody the patient cannot make. It does not repair the genetic defect and it is not given to damp down an overactive immune response. That is the distinction behind the word replacement, and it is why the dose used in CVID looks nothing like an autoimmune dose.
How is replacement dosing different from the higher immunomodulatory doses?
Replacement dosing for primary immunodeficiency sits at 300 to 600 mg/kg of body weight every 3 to 4 weeks on most FDA labels, including Gamunex-C, Gammaked, Panzyga, Octagam 5%, Flebogamma 5% DIF and Gammagard Liquid. Several products are labeled higher: Privigen at 200 to 800 mg/kg every 3 to 4 weeks, and Bivigam, Asceniv and Gammaplex 5% each at 300 to 800 mg/kg. The Immune Deficiency Foundation describes typical starting dosing as between 400 and 600 mg/kg per month.
Immunomodulatory dosing, used for autoimmune indications such as chronic immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP), is a different order of magnitude: 2 g/kg, divided over 2 consecutive days for chronic ITP or 2 to 5 days for CIDP loading. The labeled adverse-reaction data track the difference. The Gamunex-C prescribing information reports headache in 14.9% of patients at replacement dosing for primary immunodeficiency and in 52.1% of patients in the chronic ITP trial at 2 g/kg.
Because every replacement dose is calculated in mg/kg, weight is taken at each visit. CMS's Medicare Provider Compliance Tips for intravenous immune globulin instruct providers to document "an accurate weight in kilograms before each infusion since the dosage is based mg/kg/dosage."
Which IVIG products are FDA-approved for primary immunodeficiency?
Most licensed IVIG products carry a primary humoral immunodeficiency indication. Those approved for primary immunodeficiency include Gamunex-C, Gammaked, Privigen, Panzyga, Octagam 5%, Gammagard Liquid, Gammagard Liquid ERC, Gammaplex 5% and Gammaplex 10%, Flebogamma 5% DIF and Flebogamma 10% DIF, Bivigam, Asceniv, Yimmugo and Alyglo. Gamunex-C, Gammaked, Gammagard Liquid and Gammagard Liquid ERC are labeled for both intravenous and subcutaneous administration.
One trap deserves stating plainly, because two concentrations share a brand name. Octagam 10% has no primary immunodeficiency indication; its approved uses are chronic ITP in adults and dermatomyositis in adults. Octagam 5% is the Octagam presentation approved for primary immunodeficiency. Gammagard Liquid ERC, approved June 27, 2025, carries the primary immunodeficiency indication only. No product on the list above is better than another; product choice is a prescriber decision.
Why are IVIG products not interchangeable once a patient is established on one?
IVIG products differ in stabilizer, sugar content, residual IgA and concentration, and those differences appear in the labels as contraindications rather than preferences. None of it is visible from the word IVIG alone, which is why the prescriber names a specific product and why continuity of product between infusions matters.
| Product | Formulation detail | What the label states |
|---|---|---|
| Privigen | Contains the stabilizer L-proline | Contraindicated in patients with hyperprolinemia |
| Gammaplex 5% | Contains sorbitol | Contraindicated in hereditary intolerance to fructose |
| Gammagard Liquid | IgA approximately 37 micrograms/mL | Contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity |
| Gammagard Liquid ERC | IgA at or below 2 micrograms/mL | A low-IgA option where one is needed |
| Octagam 10% (no primary immunodeficiency indication) | Contains maltose 90 mg/mL | May cause falsely elevated glucose readings on GDH-PQQ glucose meters |
How often do you need IVIG for primary immunodeficiency, and for how long?
Replacement infusions are given every 3 to 4 weeks, and for antibody deficiency the therapy is typically ongoing rather than a fixed course. The interval comes from pharmacokinetics: Beydoun and colleagues, writing in Frontiers in Neurology in 2021, report that the half-life of IgG is 21 to 30 days, "so typically IVIg infusions are initiated with 3-4-week intervals." Serum IgG then falls to a trough before the next infusion; the Immune Deficiency Foundation notes that low troughs may be associated with fatigue or breakthrough infections, and that IVIG infusions typically take between 2 and 6 hours.
An indefinite three-to-four-week schedule makes a reachable, consistent infusion location a practical part of care. Prime Infusions centers include the Manhattan infusion center on the Upper East Side, the Brooklyn infusion center on Foster Avenue and the Great Neck infusion center in Nassau County, and Prime Infusions also provides home infusion where the treating practitioner orders it.
Subcutaneous immunoglobulin (SCIG) is the other route used in antibody deficiency, given weekly or biweekly, with a steadier IgG level and mostly local rather than systemic reactions. Our article comparing intravenous and subcutaneous immunoglobulin sets out the labeled differences.
What is an IgG trough level, and what do payers want documented?
An IgG trough is the serum IgG measured just before the next infusion, at the lowest point of the dosing cycle. It is the value used to judge whether replacement dosing is adequate, and it is also a documentation requirement. Aetna Clinical Policy Bulletin 0206, last reviewed June 18, 2026, requires for continued authorization in primary immunodeficiency both a reduction in the frequency of bacterial infections since therapy began and IgG trough levels monitored at least yearly.
For initial authorization the same policy sets pretreatment IgG thresholds: less than 200 mg/dL for SCID or agammaglobulinemia, and less than 500 mg/dL or at least 2 standard deviations below the mean for age for CVID and hypogammaglobulinemia. CVID additionally requires age 2 years or older and exclusion of secondary causes. Every primary antibody deficiency in that policy also requires a documented impaired antibody response to pneumococcal polysaccharide vaccine, the element most often missing from a submitted file.
Aetna Clinical Policy Bulletin 0206 is one worked example, not a general rule; requirements differ by plan. Coverage is determined by your health plan, and Prime Infusions verifies benefits and submits the authorization request. Our article on IVIG prior authorization in New York explains what plans commonly ask for.
Does Medicare cover IVIG given at home for primary immunodeficiency?
Medicare has a benefit specific to this indication and no other. Social Security Act section 1861(zz) covers intravenous immune globulin when the patient has a diagnosed primary immune deficiency disease, the IVIG is administered in the patient's home, and the treating practitioner has determined that home administration is medically appropriate. Section 4134 of the Consolidated Appropriations Act, 2023 made that in-home coverage permanent effective January 1, 2024, replacing the time-limited Medicare IVIG Demonstration; CMS states there is no longer any need to enroll in the demonstration.
Payment for the home items and services is separate from payment for the drug. It is billed under HCPCS code Q2052 at the 2026 fee schedule amount of $442.19 per visit published by Noridian, and Medicare pays 80% of the lesser of the actual charge or the fee schedule amount under 42 CFR 414.1700(a). CMS defines home to include an institution used as a residence, but a hospital, critical access hospital or skilled nursing facility is not an eligible home setting.
Use of the benefit is still limited: the CMS Home IVIG Monitoring Report published in March 2026 recorded 2,775 beneficiaries receiving home IVIG visits as of the second quarter of 2025, up from 1,637 in the first quarter of 2023. Eligibility in an individual case is determined by Medicare and the treating practitioner, and the benefit does not extend to CIDP, ITP or other immunoglobulin indications.
How do you start immunoglobulin replacement with Prime Infusions?
Patients and caregivers can send a request through the IVIG request form; referring physicians can send an order and chart notes through the Prime Infusions referrals page. Prime Infusions can be reached at 718-443-4000, fax 718-443-5000, or office@primeinfusions.com, and our IVIG treatment page covers the therapy in more detail.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. IVIG products carry an FDA boxed warning for thrombosis and for renal dysfunction and acute renal failure; review the full prescribing information for the product prescribed to you and discuss your individual risk factors with your treating clinician. Coverage and out-of-pocket cost are determined by your health plan.